APA (7th ed.) Citation

I, S., I, U., RSG, E., JGT, A., HMW, V., JHW, d. W., . . . PR, d. R. (2022). In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival. Annals of surgical oncology, 29(8), 5256. https://doi.org/10.1245/s10434-022-11718-7

Chicago Style (17th ed.) Citation

I, Said, Ubink I, Ewalds RSG, Arkesteijn JGT, Verheul HMW, de Wilt JHW, Dekker HM, Bremers AJA, and de Reuver PR. "In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging Is Not a Prognostic Marker for Survival." Annals of Surgical Oncology 29, no. 8 (2022): 5256. https://doi.org/10.1245/s10434-022-11718-7.

MLA (9th ed.) Citation

I, Said, et al. "In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging Is Not a Prognostic Marker for Survival." Annals of Surgical Oncology, vol. 29, no. 8, 2022, p. 5256, https://doi.org/10.1245/s10434-022-11718-7.